Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk (2015)
- Authors:
- Autor USP: REGO, EDUARDO MAGALHÃES - FMRP
- Unidade: FMRP
- DOI: 10.1093/annonc/mdv317
- Subjects: NEOPLASIAS; HEMATOLOGIA; RIM; ÁCIDO ÚRICO; DOENÇAS HEMATOLÓGICAS
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of Oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 26, n. 10, p. 2155-2161, 2015
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SPINA, M. et al. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, v. 26, n. 10, p. 2155-2161, 2015Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdv317. Acesso em: 12 fev. 2026. -
APA
Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., et al. (2015). Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26( 10), 2155-2161. doi:10.1093/annonc/mdv317 -
NLM
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1093/annonc/mdv317 -
Vancouver
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1093/annonc/mdv317 - Altered setmar expression associates with clinical characteristicsin chronic lymphocytic leukemia
- Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study
- Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia
- Tromboembolismo venoso
- The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia. [Carta]
- Development and evaluation of hematology-oriented clinical research training program in Latin America
- Tratamento das infecções em pacientes com pancitopenia secundária a tratamento citorredutor
- Pletora
- Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency
- The challenge of timely diagnosis and management of acute leukemias and associated infections in Latin America
Informações sobre o DOI: 10.1093/annonc/mdv317 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
